Our data from 19 different cancers indicates that NDRG2 is up-regulated in around 8% of all tumors examined, unaltered in 62% of all cases and that approximately a third of the tumor samples show down-regulation of NDRG2 compared to the corresponding normal tissue. The gene discussed is NDRG2; the disease is cancer.